OHI Stock Analysis: Omega Healthcare Investors | NYSE
REIT - Healthcare Facilities | NYSE, USA | Market Cap: 14.809m USD | 12M Return: 15.1% | US6819361006 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 74.1M
EPS Trend: 94.9%
Qual. Beats: 1
Rev. Trend: 98.9%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Omega Healthcare Investors (NYSE: OHI) is a self-managed Real Estate Investment Trust (REIT) that provides financing and capital to the long-term healthcare sector, primarily through triple-net lease structures with third-party operators. The companys portfolio is concentrated in skilled nursing and assisted living facilities, including UK care homes, spanning 1,024 operating facilities across 42 U.S. states, the District of Columbia, and the UK/Jersey, leased to 88 different operators as of September 30, 2025. As a REIT, Omega is required to distribute at least 90% of its taxable income to shareholders, which generally results in a dividend-oriented investment profile. The company is headquartered in Hunt Valley, Maryland, has been publicly traded since 1992, and falls within the GICS Health Care REITs sub-industry.
- Skilled nursing occupancy recovery lifts operator rent coverage and cash flows
- Federal Reserve rate cuts compress dividend yield spread versus Treasuries
- Medicaid reimbursement rate increases support skilled nursing operator profitability
| Net Income: 858.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 1.61 > 1.0 |
| NWC/Revenue: -2.53% < 20% (prev 219.5%; Δ -222.0% < -1%) |
| CFO/TA 0.09 > 3% & CFO 890.6m > Net Income 858.3m |
| Net Debt (3.98b) to EBITDA (1.45b): 2.75 < 3 |
| Current Ratio: 0.91 > 1.5 & < 3 |
| Outstanding Shares: last quarter (316.2m) vs 12m ago 4.29% < -2% |
| Gross Margin: 71.96% > 18% (prev 98.78%; Δ -26.82% > 0.5%) |
| Asset Turnover: 12.55% > 50% (prev 10.57%; Δ 1.98% > 0%) |
| Interest Coverage Ratio: 5.38 > 6 (EBIT TTM 1.12b / Interest Expense TTM 207.8m) |
| A: -0.00 (Total Current Assets 315.1m - Total Current Liabilities 347.9m) / Total Assets 10.0b |
| B: -0.35 (Retained Earnings -3.51b / Total Assets 10.0b) |
| C: 0.11 (EBIT TTM 1.12b / Avg Total Assets 10.3b) |
| D: 1.23 (Book Value of Equity 5.39b / Total Liabilities 4.37b) |
| Altman-Z'' = 0.86 = B |
| DSRI: 0.12 (Receivables 276.1m/2.02b, Revenue 1.29b/1.11b) |
| GMI: 1.37 (GM 98.78% / 71.96%) |
| AQI: 3.35 (AQ_t 0.30 / AQ_t-1 0.09) |
| SGI: 1.16 (Revenue 1.29b / 1.11b) |
| TATA: -0.00 (NI 858.3m - CFO 890.6m) / TA 10.0b) |
| Beneish M = -1.91 (Cap -4..+1) = B |
As of September 09, 2026, the stock is trading at USD 47.03 with a total of 2,061,748 shares traded. Over the past week, the price has changed by +2.87%, over one month by -0.76%, over three months by +8.84% and over the past year by +15.09%.
Current recommended Stop Loss: 45.30 (which is 3.7% or 2 ATR below the current price).
Omega Healthcare Investors has received a consensus analysts rating of 3.69. Therefore, it is recommended to hold OHI.
- StrongBuy: 4
- Buy: 3
- Hold: 9
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 51.9 | 10.3% |
P/E Trailing = 16.5053
P/E Forward = 10.1317
P/S = 11.7405
P/B = 2.6442
P/EG = 11.994
Revenue TTM = 1.29b USD
EBIT TTM = 1.12b USD
EBITDA TTM = 1.45b USD
Long Term Debt = 4.02b USD (from longTermDebt, last quarter)
Short Term Debt = 6.00m USD (from shortTermDebt, last quarter)
Debt = 4.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.98b USD (calculated: Debt 4.02b - CCE 39.0m)
Enterprise Value = 18.8b USD (14.8b + Debt 4.02b - CCE 39.0m)
Interest Coverage Ratio = 5.38 (Ebit TTM 1.12b / Interest Expense TTM 207.8m)
EV/FCF = 20.80x (Enterprise Value 18.8b / FCF TTM 903.3m)
FCF Yield = 4.81% (FCF TTM 903.3m / Enterprise Value 18.8b)
FCF Margin = 69.92% (FCF TTM 903.3m / Revenue TTM 1.29b)
Net Margin = 66.43% (Net Income TTM 858.3m / Revenue TTM 1.29b)
Gross Margin = 71.96% ((Revenue TTM 1.29b - Cost of Revenue TTM 362.3m) / Revenue TTM)
Gross Margin QoQ = 46.41% (prev none%)
Tobins Q-Ratio = 1.87 (Enterprise Value 18.8b / Total Assets 10.0b)
Interest Expense / Debt = 5.17% (Interest Expense 207.8m / Debt 4.02b)
Taxrate = 1.79% (16.3m / 911.5m)
NOPAT = 1.10b (EBIT 1.12b * (1 - 1.79%))
Current Ratio = 0.91 (Total Current Assets 315.1m / Total Current Liabilities 347.9m)
Debt / Equity = 0.75 (Debt 4.02b / totalStockholderEquity, last quarter 5.39b)
Debt / EBITDA = 2.75 (Net Debt 3.98b / EBITDA 1.45b)
Debt / FCF = 4.41 (Net Debt 3.98b / FCF TTM 903.3m)
Total Stockholder Equity = 5.20b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.34% (Net Income 858.3m / Total Assets 10.0b)
RoE = 16.51% (Net Income TTM 858.3m / Total Stockholder Equity 5.20b)
RoCE = 12.12% (EBIT 1.12b / Capital Employed (Equity 5.20b + L.T.Debt 4.02b))
RoIC = 11.36% (NOPAT 1.10b / Invested Capital 9.66b)
WACC = 5.22% (E(14.8b)/V(18.8b) * Re(5.26%) + D(4.02b)/V(18.8b) * Rd(5.17%) * (1-Tc(0.02)))
Discount Rate = 5.26% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.89 | Cagr: 9.61%
[DCF] Terminal Value 77.97% ; FCFF base≈853.8m ; Y1≈978.8m ; Y5≈1.44b
[DCF] Fair Price = 58.41 (EV 21.7b - Net Debt 3.98b = Equity 17.7b / Shares 303.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 94.93 | EPS CAGR: 21.69% | SUE: 0.90 | # QB: 1
Revenue Correlation: 98.91 | Revenue CAGR: 14.18% | SUE: 0.80 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.49 | Chg30d=+3.89% | Revisions=-25% | Analysts=4
EPS current Year (2026-12-31): EPS=1.98 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=-2.7% | GrowthRev=+10.6%
EPS next Year (2027-12-31): EPS=2.02 | Chg30d=-1.05% | Revisions=+0% | GrowthEPS=+2.2% | GrowthRev=+6.4%
[Analyst] Revisions Ratio: -17% (up=1, down=2)